Genomics company is planning a free float of at least 25% of its shares in the initial public offering
Interest in its active pharmaceutical ingredients operations, including French arm, which generated R6.4bn of R37.8bn revenue in financial 2021
Fear of side-effects and mistrust of the government emerge as key reasons for not getting vaccinated
SPONSORED | Listen to episode 1 of the three-part podcast series by Discovery Health
Distributors say 42 states, five territories and Washington have signed on to deal resolving claims they fuelled opioid epidemic
The group aims at procurement from independent power producers to be carbon neutral by 2030
It’s a moral imperative, says CEO Adrian Gore, after the company lost 14,000 clients to Covid-19
Aspen has capacity to produce 1.35-billion vaccine doses at its Gqeberha facility and is now using less than a quarter of that to help make J&J’s Covid-19 shot
The trial, called Imbokodo, shows the vaccine is just 25% effective against preventing infection over two years
Mudiwa Gavaza is joined by Duane Nicol, cybersecurity expert at Mimecast
People who receive Johnson & Johnson’s one-shot Covid-19 jab could benefit from a follow-up shot later in 2021
The pharmacy group says it enjoyed strong demand in a share sale as the founding Saltzman family hands over to new management
Drug maker has been pushing into products that are not price regulated, which now contribute half of its revenue
British drugmaker's new antibody therapy reduced the risk of people developing any Covid-19 symptoms by 77% in a late-stage trial
Michael Avery and guests take a look at the progress made in the country’s Covid-19 vaccination rollout
French drugmaker posts nearly €9bn in revenue for the quarter
The US drugmaker had previously projected vaccine sales for the year of $26bn
But parallels with Tesla don’t necessarily bode well for the stock amid a debut dip
Debt-ravaged group is selling off businesses to avoid business rescue.
